{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:01:47Z","timestamp":1784782907757,"version":"3.55.0"},"publisher-location":"New York, NY","reference-count":229,"publisher":"Springer US","isbn-type":[{"value":"9781071627716","type":"print"},{"value":"9781071627723","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-2772-3_1","type":"book-chapter","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T18:07:03Z","timestamp":1668794823000},"page":"3-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Current Strategies of Muscular Dystrophy Therapeutics: An Overview"],"prefix":"10.1007","author":[{"given":"Kenji Rowel Q.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","volume":"394","author":"E Mercuri","year":"2019","unstructured":"Mercuri E, B\u00f6nnemann CG, Muntoni F (2019) Muscular dystrophies. Lancet 394:2025\u20132038. https:\/\/doi.org\/10.1016\/S0140-6736(19)32910-1","journal-title":"Lancet"},{"key":"1_CR2","doi-asserted-by":"publisher","unstructured":"Mercuri E, Muntoni F (2013) Muscular dystrophies. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(12)61897-2","DOI":"10.1016\/S0140-6736(12)61897-2"},{"key":"1_CR3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/WCO.0000000000000739","volume":"32","author":"MA Waldrop","year":"2019","unstructured":"Waldrop MA, Flanigan KM (2019) Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol 32:722\u2013727. https:\/\/doi.org\/10.1097\/WCO.0000000000000739","journal-title":"Curr Opin Neurol"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.spen.2011.10.010","volume":"18","author":"E Bertini","year":"2011","unstructured":"Bertini E, D\u2019Amico A, Gualandi F, Petrini S (2011) Congenital muscular dystrophies: a brief review. Semin Pediatr Neurol 18:277\u2013288. https:\/\/doi.org\/10.1016\/j.spen.2011.10.010","journal-title":"Semin Pediatr Neurol"},{"key":"1_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-8651-4_1","volume-title":"Exon skipping: methods and protocols","author":"KRQ Lim","year":"2018","unstructured":"Lim KRQ, Yokota T (2018) Invention and early history of exon skipping and splice modulation. In: Yokota T, Maruyama R (eds) Exon skipping: methods and protocols. Springer, New York, pp 3\u201330"},{"key":"1_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-0716-0771-8_1","volume-title":"Gapmers methods protocols","author":"KRQ Lim","year":"2020","unstructured":"Lim KRQ, Yokota T (2020) Invention and early history of gapmers. In: Yokota T, Maruyama R (eds) Gapmers methods protocols. Springer, pp 3\u201319"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJA Lee","year":"2013","unstructured":"Lee JJA, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3:144\u2013176. https:\/\/doi.org\/10.3390\/jpm3030144","journal-title":"J Pers Med"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/nar\/7.1.179","volume":"7","author":"H Donis-Keller","year":"1979","unstructured":"Donis-Keller H (1979) Site specific enzymatic cleavage of RNA. Nucleic Acids Res 7:179\u2013192. https:\/\/doi.org\/10.1093\/nar\/7.1.179","journal-title":"Nucleic Acids Res"},{"key":"1_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0014-5793(87)80171-0","volume":"215","author":"H Inoue","year":"1987","unstructured":"Inoue H, Hayase Y, Iwai S, Ohtsuka E (1987) Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett 215:327\u2013330","journal-title":"FEBS Lett"},{"key":"1_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919\u2013928. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4","journal-title":"Cell"},{"key":"1_CR11","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","volume":"90","author":"BJ Petrof","year":"1993","unstructured":"Petrof BJ, Shrager JB, Stedman HH et al (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 90:3710\u20133714. https:\/\/doi.org\/10.1073\/pnas.90.8.3710","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1083\/jcb.122.4.809","volume":"122","author":"JM Ervasti","year":"1993","unstructured":"Ervasti JM, Campbell KP (1993) A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 122:809\u2013823. https:\/\/doi.org\/10.1083\/jcb.122.4.809","journal-title":"J Cell Biol"},{"key":"1_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbadis.2006.05.010","volume":"1772","author":"JM Ervasti","year":"2007","unstructured":"Ervasti JM (2007) Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim Biophys Acta 1772:108\u2013117. https:\/\/doi.org\/10.1016\/j.bbadis.2006.05.010","journal-title":"Biochim Biophys Acta"},{"key":"1_CR14","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","volume":"5","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, McNally EM (2015) The dystrophin complex: structure, function, and implications for therapy. Compr Physiol 5:1223\u20131239. https:\/\/doi.org\/10.1002\/cphy.c140048","journal-title":"Compr Physiol"},{"key":"1_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S et al (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90\u201395. https:\/\/doi.org\/10.1016\/0888-7543(88)90113-9","journal-title":"Genomics"},{"key":"1_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/jpm10040241","volume":"10","author":"KRQ Lim","year":"2020","unstructured":"Lim KRQ, Nguyen Q, Yokota T (2020) Genotype\u2013phenotype correlations in Duchenne and Becker muscular dystrophy patients from the Canadian Neuromuscular Disease Registry. J Pers Med 10:241. https:\/\/doi.org\/10.3390\/jpm10040241","journal-title":"J Pers Med"},{"key":"1_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S et al (2015) The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36:395\u2013402. https:\/\/doi.org\/10.1002\/humu.22758","journal-title":"Hum Mutat"},{"key":"1_CR18","first-page":"725","volume":"56","author":"LT Thanh","year":"1995","unstructured":"Thanh LT, Nguyen TM, Helliwell TR, Morris GE (1995) Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am J Hum Genet 56:725\u2013731","journal-title":"Am J Hum Genet"},{"key":"1_CR19","first-page":"950","volume":"50","author":"CJ Klein","year":"1992","unstructured":"Klein CJ, Coovert DD, Bulman DE et al (1992) Somatic reversion\/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 50:950\u2013959","journal-title":"Am J Hum Genet"},{"key":"1_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/humu.20913","volume":"30","author":"OL Gurvich","year":"2009","unstructured":"Gurvich OL, Maiti B, Weiss RB et al (2009) DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6. Hum Mutat 30:633\u2013640. https:\/\/doi.org\/10.1002\/humu.20913","journal-title":"Hum Mutat"},{"key":"1_CR21","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/nm.3628","volume":"20","author":"N Wein","year":"2014","unstructured":"Wein N, Vulin A, Falzarano MS et al (2014) Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat Med 20:992\u20131000. https:\/\/doi.org\/10.1038\/nm.3628","journal-title":"Nat Med"},{"key":"1_CR22","first-page":"158","volume":"56","author":"AV Winnard","year":"1995","unstructured":"Winnard AV, Mendell JR, Prior TW et al (1995) Frameshift deletions of exons 3-7 and revertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production. Am J Hum Genet 56:158\u2013166. 7825572","journal-title":"Am J Hum Genet"},{"key":"1_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S et al (2021) Duchenne muscular dystrophy. Nat Rev Dis Prim 7:13. https:\/\/doi.org\/10.1038\/s41572-021-00248-3","journal-title":"Nat Rev Dis Prim"},{"key":"1_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/JCI117693","volume":"95","author":"Y Takeshima","year":"1995","unstructured":"Takeshima Y, Nishio H, Sakamoto H et al (1995) Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J Clin Invest 95:515\u2013520. https:\/\/doi.org\/10.1172\/JCI117693","journal-title":"J Clin Invest"},{"key":"1_CR25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQKRQ Lim","year":"2017","unstructured":"Lim KRQKRQ, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/DDDT.S97635","journal-title":"Drug Des Devel Ther"},{"key":"1_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","volume":"56","author":"S Anwar","year":"2020","unstructured":"Anwar S, Yokota T (2020) Golodirsen for Duchenne muscular dystrophy. Drugs Today 56:491\u2013504. https:\/\/doi.org\/10.1358\/dot.2020.56.8.3159186","journal-title":"Drugs Today"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","volume":"55","author":"RR Roshmi","year":"2019","unstructured":"Roshmi RR, Yokota T (2019) Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today 55:627\u2013639. https:\/\/doi.org\/10.1358\/dot.2019.55.10.3045038","journal-title":"Drugs Today"},{"key":"1_CR28","doi-asserted-by":"publisher","unstructured":"Shirley M (2021) Casimersen: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-021-01512-2","DOI":"10.1007\/s40265-021-01512-2"},{"key":"1_CR29","doi-asserted-by":"publisher","unstructured":"Miyatake S, Mizobe Y, Tsoumpra MK et al (2019) Scavenger receptor class A1 mediates uptake of morpholino antisense oligonucleotide into dystrophic skeletal muscle. Mol Ther \u2013 Nucleic Acids. https:\/\/doi.org\/10.1016\/j.omtn.2019.01.008","DOI":"10.1016\/j.omtn.2019.01.008"},{"key":"1_CR30","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","volume":"94","author":"DE Frank","year":"2020","unstructured":"Frank DE, Schnell FJ, Akana C et al (2020) Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology 94:e2270\u2013e2282. https:\/\/doi.org\/10.1212\/WNL.0000000000009233","journal-title":"Neurology"},{"key":"1_CR31","unstructured":"Wagner KR, Kuntz N, Koenig E et al (2020) Casimersen treatment in patients with duchenne muscular dystrophy: safety, tolerability, and pharmacokinetics over 144 weeks of treatment. https:\/\/investorrelations.sarepta.com\/static-files\/4fd181c5-73ec-4c89-ba29-e25ea2b7c776. Accessed 29 Apr 2021"},{"key":"1_CR32","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/acn3.51235","volume":"7","author":"H Komaki","year":"2020","unstructured":"Komaki H, Takeshima Y, Matsumura T et al (2020) Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1\/2 study. Ann Clin Transl Neurol 7:2393\u20132408. https:\/\/doi.org\/10.1002\/acn3.51235","journal-title":"Ann Clin Transl Neurol"},{"key":"1_CR33","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM et al (2020) Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping. JAMA Neurol 77:982. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1264","journal-title":"JAMA Neurol"},{"key":"1_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000089","volume":"2","author":"E Harris","year":"2016","unstructured":"Harris E, Bladen CL, Mayhew A et al (2016) The clinical outcome study for dysferlinopathy. Neurol Genet 2:e89. https:\/\/doi.org\/10.1212\/NXG.0000000000000089","journal-title":"Neurol Genet"},{"key":"1_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/mus.25367","volume":"54","author":"M Fanin","year":"2016","unstructured":"Fanin M, Angelini C (2016) Progress and challenges in diagnosis of dysferlinopathy. Muscle Nerve 54:821\u2013835. https:\/\/doi.org\/10.1002\/mus.25367","journal-title":"Muscle Nerve"},{"key":"1_CR36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nature01573","volume":"423","author":"D Bansal","year":"2003","unstructured":"Bansal D, Miyake K, Vogel SS et al (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423:168\u2013172. https:\/\/doi.org\/10.1038\/nature01573","journal-title":"Nature"},{"key":"1_CR37","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.omtn.2018.10.004","volume":"13","author":"JJA Lee","year":"2018","unstructured":"Lee JJA, Maruyama R, Duddy W et al (2018) Identification of novel antisense-mediated exon skipping targets in DYSF for therapeutic treatment of dysferlinopathy. Mol Ther \u2013 Nucleic Acids 13:596\u2013604. https:\/\/doi.org\/10.1016\/j.omtn.2018.10.004","journal-title":"Mol Ther \u2013 Nucleic Acids"},{"key":"1_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3233\/JND-150109","volume":"2","author":"F Barth\u00e9l\u00e9my","year":"2015","unstructured":"Barth\u00e9l\u00e9my F, Blouin C, Wein N et al (2015) Exon 32 skipping of dysferlin rescues membrane repair in patients\u2019 cells. J Neuromuscul Dis 2:281\u2013290. https:\/\/doi.org\/10.3233\/JND-150109","journal-title":"J Neuromuscul Dis"},{"key":"1_CR39","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ejhg.2010.4","volume":"18","author":"A Aartsma-Rus","year":"2010","unstructured":"Aartsma-Rus A, Singh KHK, Fokkema IFAC et al (2010) Therapeutic exon skipping for dysferlinopathies? Eur J Hum Genet 18:889\u2013894. https:\/\/doi.org\/10.1038\/ejhg.2010.4","journal-title":"Eur J Hum Genet"},{"key":"1_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1089\/nat.2019.0788","volume":"30","author":"N Verwey","year":"2020","unstructured":"Verwey N, Gazzoli I, Krause S et al (2020) Antisense-mediated skipping of dysferlin exons in control and dysferlinopathy patient-derived cells. Nucleic Acid Ther 30:71\u201379. https:\/\/doi.org\/10.1089\/nat.2019.0788","journal-title":"Nucleic Acid Ther"},{"key":"1_CR41","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.270.5237.819","volume":"270","author":"S Noguchi","year":"1995","unstructured":"Noguchi S, McNally EM, Othmane KB et al (1995) Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science (80- ) 270:819\u2013822. https:\/\/doi.org\/10.1126\/science.270.5237.819","journal-title":"Science (80- )"},{"key":"1_CR42","first-page":"1040","volume":"59","author":"EM McNally","year":"1996","unstructured":"McNally EM, Passos-Bueno MR, B\u00f6nnemann CG et al (1996) Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation. Am J Hum Genet 59:1040\u20131047","journal-title":"Am J Hum Genet"},{"key":"1_CR43","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1172\/JCI82768","volume":"125","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, Wyatt E, Goldstein JA et al (2015) Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping. J Clin Invest 125:4186\u20134195. https:\/\/doi.org\/10.1172\/JCI82768","journal-title":"J Clin Invest"},{"key":"1_CR44","doi-asserted-by":"publisher","unstructured":"Wyatt EJ, Demonbreun AR, Kim EY et al (2018) Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.99357","DOI":"10.1172\/jci.insight.99357"},{"key":"1_CR45","doi-asserted-by":"publisher","unstructured":"Demonbreun AR, Wyatt EJ, Fallon KS et al (2019) A gene-edited mouse model of Limb-Girdle muscular dystrophy 2C for testing exon skipping. Dis Model Mech. https:\/\/doi.org\/10.1242\/dmm.040832","DOI":"10.1242\/dmm.040832"},{"key":"1_CR46","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","volume":"22","author":"Y Aoki","year":"2013","unstructured":"Aoki Y, Nagata T, Yokota T et al (2013) Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-\u03b12 chain-null congenital muscular dystrophy mice. Hum Mol Genet 22:4914\u20134928. https:\/\/doi.org\/10.1093\/hmg\/ddt341","journal-title":"Hum Mol Genet"},{"key":"1_CR47","first-page":"351","volume":"317","author":"FM Tom\u00e9","year":"1994","unstructured":"Tom\u00e9 FM, Evangelista T, Leclerc A et al (1994) Congenital muscular dystrophy with merosin deficiency. C R Acad Sci III 317:351\u2013357","journal-title":"C R Acad Sci III"},{"key":"1_CR48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/ng1095-216","volume":"11","author":"A Helbling-Leclerc","year":"1995","unstructured":"Helbling-Leclerc A, Zhang X, Topaloglu H et al (1995) Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet 11:216\u2013218. https:\/\/doi.org\/10.1038\/ng1095-216","journal-title":"Nat Genet"},{"key":"1_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/bs.ctm.2015.05.002","volume":"76","author":"M Durbeej","year":"2015","unstructured":"Durbeej M (2015) Laminin-\u03b12 chain-deficient congenital muscular dystrophy: pathophysiology and development of treatment. Curr Top Membr 76:31\u201360. https:\/\/doi.org\/10.1016\/bs.ctm.2015.05.002","journal-title":"Curr Top Membr"},{"key":"1_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.nmd.2010.02.001","volume":"20","author":"F Geranmayeh","year":"2010","unstructured":"Geranmayeh F, Clement E, Feng LH et al (2010) Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul Disord 20:241\u2013250. https:\/\/doi.org\/10.1016\/j.nmd.2010.02.001","journal-title":"Neuromuscul Disord"},{"key":"1_CR51","doi-asserted-by":"publisher","unstructured":"Wheeler TM, Lueck JD, Swanson MS et al (2007) Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI33355","DOI":"10.1172\/JCI33355"},{"key":"1_CR52","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/srep02242","volume":"3","author":"M Koebis","year":"2013","unstructured":"Koebis M, Kiyatake T, Yamaura H et al (2013) Ultrasound-enhanced delivery of morpholino with Bubble liposomes ameliorates the myotonia of myotonic dystrophy model mice. Sci Rep 3:2242. https:\/\/doi.org\/10.1038\/srep02242","journal-title":"Sci Rep"},{"key":"1_CR53","doi-asserted-by":"publisher","unstructured":"Bolduc V, Foley AR, Solomon-Degefa H et al (2019) A recurrent COL6A1 pseudoexon insertion causes muscular dystrophy and is effectively targeted by splice-correction therapies. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.124403","DOI":"10.1172\/jci.insight.124403"},{"key":"1_CR54","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omtn.2020.05.029","volume":"21","author":"S Aguti","year":"2020","unstructured":"Aguti S, Bolduc V, Ala P et al (2020) Exon-skipping oligonucleotides restore functional collagen VI by correcting a common COL6A1 mutation in Ullrich CMD. Mol Ther \u2013 Nucleic Acids 21:205\u2013216. https:\/\/doi.org\/10.1016\/j.omtn.2020.05.029","journal-title":"Mol Ther \u2013 Nucleic Acids"},{"key":"1_CR55","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1089\/hum.2012.109","volume":"23","author":"F Gualandi","year":"2012","unstructured":"Gualandi F, Manzati E, Sabatelli P et al (2012) Antisense-induced messenger depletion corrects a COL6A2 dominant mutation in Ullrich myopathy. Hum Gene Ther 23:1313\u20131318. https:\/\/doi.org\/10.1089\/hum.2012.109","journal-title":"Hum Gene Ther"},{"key":"1_CR56","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1189044","volume":"329","author":"RJLF Lemmers","year":"2010","unstructured":"Lemmers RJLF, van der Vliet PJ, Klooster R et al (2010) A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329:1650\u20131653. https:\/\/doi.org\/10.1126\/science.1189044","journal-title":"Science"},{"key":"1_CR57","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/ng.3858","volume":"49","author":"A De Iaco","year":"2017","unstructured":"De Iaco A, Planet E, Coluccio A et al (2017) DUX-family transcription factors regulate zygotic genome activation in placental mammals. Nat Genet 49:941\u2013945. https:\/\/doi.org\/10.1038\/ng.3858","journal-title":"Nat Genet"},{"key":"1_CR58","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/ng.3844","volume":"49","author":"PG Hendrickson","year":"2017","unstructured":"Hendrickson PG, Dor\u00e1is JA, Grow EJ et al (2017) Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL\/HERVL retrotransposons. Nat Genet 49:925\u2013934. https:\/\/doi.org\/10.1038\/ng.3844","journal-title":"Nat Genet"},{"key":"1_CR59","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/hmg\/3.8.1287","volume":"3","author":"JE Hewitt","year":"1994","unstructured":"Hewitt JE, Lyle R, Clark LN et al (1994) Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystropothhy. Hum Mol Genet 3:1287\u20131295. https:\/\/doi.org\/10.1093\/hmg\/3.8.1287","journal-title":"Hum Mol Genet"},{"key":"1_CR60","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3390\/ijms21030729","volume":"21","author":"KRQKRQ Lim","year":"2020","unstructured":"Lim KRQKRQ, Nguyen Q, Yokota T (2020) DUX4 signalling in the pathogenesis of facioscapulohumeral muscular dystrophy. Int J Mol Sci 21:729. https:\/\/doi.org\/10.3390\/ijms21030729","journal-title":"Int J Mol Sci"},{"key":"1_CR61","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11910-016-0667-0","volume":"16","author":"LH Wang","year":"2016","unstructured":"Wang LH, Tawil R (2016) Facioscapulohumeral dystrophy. Curr Neurol Neurosci Rep 16:66. https:\/\/doi.org\/10.1007\/s11910-016-0667-0","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.642858","volume":"12","author":"KRQ Lim","year":"2021","unstructured":"Lim KRQ, Yokota T (2021) Genetic approaches for the treatment of facioscapulohumeral muscular dystrophy. Front Pharmacol 12:642858. https:\/\/doi.org\/10.3389\/fphar.2021.642858","journal-title":"Front Pharmacol"},{"key":"1_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026820","volume":"6","author":"C Vanderplanck","year":"2011","unstructured":"Vanderplanck C, Ansseau E, Charron S et al (2011) The FSHD atrophic myotube phenotype is caused by DUX4 expression. PLoS One 6:e26820. https:\/\/doi.org\/10.1371\/journal.pone.0026820","journal-title":"PLoS One"},{"key":"1_CR64","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/hmg\/ddw015","volume":"25","author":"A-C Marsollier","year":"2016","unstructured":"Marsollier A-C, Ciszewski L, Mariot V et al (2016) Antisense targeting of 3\u2032 end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach. Hum Mol Genet 25:1468\u20131478. https:\/\/doi.org\/10.1093\/hmg\/ddw015","journal-title":"Hum Mol Genet"},{"key":"1_CR65","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/mt.2016.111","volume":"24","author":"JC Chen","year":"2016","unstructured":"Chen JC, King OD, Zhang Y et al (2016) Morpholino-mediated knockdown of DUX4 toward facioscapulohumeral muscular dystrophy therapeutics. Mol Ther 24:1405\u20131411. https:\/\/doi.org\/10.1038\/mt.2016.111","journal-title":"Mol Ther"},{"key":"1_CR66","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/genes8030093","volume":"8","author":"E Ansseau","year":"2017","unstructured":"Ansseau E, Vanderplanck C, Wauters A et al (2017) Antisense oligonucleotides used to target the DUX4 mRNA as therapeutic approaches in faciosscapulohumeral muscular dystrophy (FSHD). Genes (Basel) 8:93. https:\/\/doi.org\/10.3390\/genes8030093","journal-title":"Genes (Basel)"},{"key":"1_CR67","doi-asserted-by":"publisher","first-page":"11301","DOI":"10.1038\/s41598-020-68135-7","volume":"10","author":"A Derenne","year":"2020","unstructured":"Derenne A, Tassin A, Nguyen TH et al (2020) Induction of a local muscular dystrophy using electroporation in vivo: an easy tool for screening therapeutics. Sci Rep 10:11301. https:\/\/doi.org\/10.1038\/s41598-020-68135-7","journal-title":"Sci Rep"},{"key":"1_CR68","doi-asserted-by":"publisher","unstructured":"Lu-Nguyen NB, Malerba A, Dickson G, Popplewell L (2021) Systemic antisense therapeutics inhibiting DUX4 expression improves muscle function in an FSHD mouse model. bioRxiv. https:\/\/doi.org\/10.1101\/2021.01.14.426659","DOI":"10.1101\/2021.01.14.426659"},{"key":"1_CR69","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","volume":"68","author":"JD Brook","year":"1992","unstructured":"Brook JD, McCurrach ME, Harley HG et al (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member. Cell 68:799\u2013808. https:\/\/doi.org\/10.1016\/0092-8674(92)90154-5","journal-title":"Cell"},{"key":"1_CR70","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1126\/science.1546326","volume":"255","author":"Y Fu","year":"1992","unstructured":"Fu Y, Pizzuti A, Fenwick R et al (1992) An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science (80- ) 255:1256\u20131258. https:\/\/doi.org\/10.1126\/science.1546326","journal-title":"Science (80- )"},{"key":"1_CR71","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1126\/science.1546325","volume":"255","author":"M Mahadevan","year":"1992","unstructured":"Mahadevan M, Tsilfidis C, Sabourin L et al (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3\u2032 untranslated region of the gene. Science (80- ) 255:1253\u20131255. https:\/\/doi.org\/10.1126\/science.1546325","journal-title":"Science (80- )"},{"key":"1_CR72","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1126\/science.280.5364.737","volume":"280","author":"AV Philips","year":"1998","unstructured":"Philips AV (1998) Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science (80- ) 280:737\u2013741. https:\/\/doi.org\/10.1126\/science.280.5364.737","journal-title":"Science (80- )"},{"key":"1_CR73","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1042\/BST0371281","volume":"37","author":"JE Lee","year":"2009","unstructured":"Lee JE, Cooper TA (2009) Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans 37:1281\u20131286. https:\/\/doi.org\/10.1042\/BST0371281","journal-title":"Biochem Soc Trans"},{"key":"1_CR74","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.cellsig.2008.05.005","volume":"20","author":"P Kaliman","year":"2008","unstructured":"Kaliman P, Llagostera E (2008) Myotonic dystrophy protein kinase (DMPK) and its role in the pathogenesis of myotonic dystrophy 1. Cell Signal 20:1935\u20131941. https:\/\/doi.org\/10.1016\/j.cellsig.2008.05.005","journal-title":"Cell Signal"},{"key":"1_CR75","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.drudis.2018.08.004","volume":"23","author":"SJ Overby","year":"2018","unstructured":"Overby SJ, Cerro-Herreros E, Llamusi B, Artero R (2018) RNA-mediated therapies in myotonic dystrophy. Drug Discov Today 23:2013\u20132022. https:\/\/doi.org\/10.1016\/j.drudis.2018.08.004","journal-title":"Drug Discov Today"},{"key":"1_CR76","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41467-018-04892-4","volume":"9","author":"E Cerro-Herreros","year":"2018","unstructured":"Cerro-Herreros E, Sabater-Arcis M, Fernandez-Costa JM et al (2018) miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models. Nat Commun 9:2482. https:\/\/doi.org\/10.1038\/s41467-018-04892-4","journal-title":"Nat Commun"},{"key":"1_CR77","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.omtn.2020.07.021","volume":"21","author":"E Cerro-Herreros","year":"2020","unstructured":"Cerro-Herreros E, Gonz\u00e1lez-Mart\u00ednez I, Moreno-Cervera N et al (2020) Therapeutic potential of antagomiR-23b for treating myotonic dystrophy. Mol Ther \u2013 Nucleic Acids 21:837\u2013849. https:\/\/doi.org\/10.1016\/j.omtn.2020.07.021","journal-title":"Mol Ther \u2013 Nucleic Acids"},{"key":"1_CR78","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2044-5040-1-22","volume":"1","author":"F Saito","year":"2011","unstructured":"Saito F, Matsumura K (2011) Fukuyama-type congenital muscular dystrophy and defective glycosylation of \u03b1-dystroglycan. Skelet Muscle 1:22. https:\/\/doi.org\/10.1186\/2044-5040-1-22","journal-title":"Skelet Muscle"},{"key":"1_CR79","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/28653","volume":"394","author":"K Kobayashi","year":"1998","unstructured":"Kobayashi K, Nakahori Y, Miyake M et al (1998) An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394:388\u2013392. https:\/\/doi.org\/10.1038\/28653","journal-title":"Nature"},{"key":"1_CR80","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/ng1193-283","volume":"5","author":"T Toda","year":"1993","unstructured":"Toda T, Segawa M, Nomura Y et al (1993) Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31\u201333. Nat Genet 5:283\u2013286. https:\/\/doi.org\/10.1038\/ng1193-283","journal-title":"Nat Genet"},{"key":"1_CR81","doi-asserted-by":"publisher","first-page":"8398","DOI":"10.1074\/jbc.M111.300905","volume":"287","author":"M Tachikawa","year":"2012","unstructured":"Tachikawa M, Kanagawa M, Yu C-C et al (2012) Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration. J Biol Chem 287:8398\u20138406. https:\/\/doi.org\/10.1074\/jbc.M111.300905","journal-title":"J Biol Chem"},{"key":"1_CR82","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature10456","volume":"478","author":"M Taniguchi-Ikeda","year":"2011","unstructured":"Taniguchi-Ikeda M, Kobayashi K, Kanagawa M et al (2011) Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 478:127\u2013131. https:\/\/doi.org\/10.1038\/nature10456","journal-title":"Nature"},{"key":"1_CR83","doi-asserted-by":"publisher","first-page":"16509","DOI":"10.1073\/pnas.1909649117","volume":"117","author":"KRQ Lim","year":"2020","unstructured":"Lim KRQ, Maruyama R, Echigoya Y et al (2020) Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy. Proc Natl Acad Sci 117:16509\u201316515. https:\/\/doi.org\/10.1073\/pnas.1909649117","journal-title":"Proc Natl Acad Sci"},{"key":"1_CR84","doi-asserted-by":"publisher","unstructured":"Lim KRQ, Bittel A, Maruyama R et al (2020) DUX4 transcript knockdown with antisense 2\u2032-O-methoxyethyl gapmers for the treatment of facioscapulohumeral muscular dystrophy. Mol Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2020.10.010","DOI":"10.1016\/j.ymthe.2020.10.010"},{"key":"1_CR85","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.3390\/ijms21155575","volume":"21","author":"AJ Bittel","year":"2020","unstructured":"Bittel AJ, Sreetama SC, Bittel DC et al (2020) Membrane repair deficit in facioscapulohumeral muscular dystrophy. Int J Mol Sci 21:5575. https:\/\/doi.org\/10.3390\/ijms21155575","journal-title":"Int J Mol Sci"},{"key":"1_CR86","doi-asserted-by":"crossref","unstructured":"Nguyen Q, Yokota T (2020) Degradation of toxic RNA in myotonic dystrophy using gapmer antisense. Oligonucleotides:99\u2013109","DOI":"10.1007\/978-1-0716-0771-8_7"},{"key":"1_CR87","unstructured":"Myotonic Dystrophy Foundation (2017) Ionis pharmaceuticals reports on DMPKRx phase 1\/2 clinical trial. https:\/\/us8.campaign-archive.com\/?u=8f5969cac3271759ce78c8354&id=8cc67ae9b8&e=cd1f4d18fe. Accessed 7 June 2021"},{"key":"1_CR88","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrneurol.2011.81","volume":"7","author":"CG B\u00f6nnemann","year":"2011","unstructured":"B\u00f6nnemann CG (2011) The collagen VI-related myopathies: muscle meets its matrix. Nat Rev Neurol 7:379\u2013390. https:\/\/doi.org\/10.1038\/nrneurol.2011.81","journal-title":"Nat Rev Neurol"},{"key":"1_CR89","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/2044-5040-1-30","volume":"1","author":"V Allamand","year":"2011","unstructured":"Allamand V, Bri\u00f1as L, Richard P et al (2011) ColVI myopathies: where do we stand, where do we go? Skelet Muscle 1:30. https:\/\/doi.org\/10.1186\/2044-5040-1-30","journal-title":"Skelet Muscle"},{"key":"1_CR90","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.omtn.2017.07.006","volume":"8","author":"E Marrosu","year":"2017","unstructured":"Marrosu E, Ala P, Muntoni F, Zhou H (2017) Gapmer antisense oligonucleotides suppress the mutant allele of COL6A3 and restore functional protein in Ullrich muscular dystrophy. Mol Ther \u2013 Nucleic Acids 8:416\u2013427. https:\/\/doi.org\/10.1016\/j.omtn.2017.07.006","journal-title":"Mol Ther \u2013 Nucleic Acids"},{"key":"1_CR91","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.22283","volume":"69","author":"AR Foley","year":"2011","unstructured":"Foley AR, Hu Y, Zou Y et al (2011) Large genomic deletions: a novel cause of Ullrich congenital muscular dystrophy. Ann Neurol 69:206\u2013211. https:\/\/doi.org\/10.1002\/ana.22283","journal-title":"Ann Neurol"},{"key":"1_CR92","doi-asserted-by":"publisher","unstructured":"Gadgil A, Raczy\u0144ska KD (2021) U7 snRNA: a tool for gene therapy. J Gene Med. https:\/\/doi.org\/10.1002\/jgm.3321","DOI":"10.1002\/jgm.3321"},{"key":"1_CR93","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev-biophys-083012-130404","volume":"42","author":"RC Wilson","year":"2013","unstructured":"Wilson RC, Doudna JA (2013) Molecular mechanisms of RNA interference. Annu Rev Biophys 42:217\u2013239. https:\/\/doi.org\/10.1146\/annurev-biophys-083012-130404","journal-title":"Annu Rev Biophys"},{"key":"1_CR94","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","volume":"16","author":"J Zhou","year":"2017","unstructured":"Zhou J, Rossi J (2017) Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov 16:181\u2013202. https:\/\/doi.org\/10.1038\/nrd.2016.199","journal-title":"Nat Rev Drug Discov"},{"key":"1_CR95","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/12_2011_139","volume-title":"Nucleic acid drugs","author":"MK Osako","year":"2011","unstructured":"Osako MK, Nakagami H, Morishita R (2011) Development and modification of decoy oligodeoxynucleotides for clinical application. In: Nucleic acid drugs. Springer, Berlin\/Heidelberg, pp 49\u201359"},{"key":"1_CR96","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.mib.2011.03.005","volume":"14","author":"MP Terns","year":"2011","unstructured":"Terns MP, Terns RM (2011) CRISPR-based adaptive immune systems. Curr Opin Microbiol 14:321\u2013327. https:\/\/doi.org\/10.1016\/j.mib.2011.03.005","journal-title":"Curr Opin Microbiol"},{"key":"1_CR97","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali P, Yang L, Esvelt KM et al (2013) RNA-guided human genome engineering via Cas9. Science 339:823\u2013826. https:\/\/doi.org\/10.1126\/science.1232033","journal-title":"Science"},{"key":"1_CR98","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang F, Doudna JA (2017) CRISPR-Cas9 structures and mechanisms. Annu Rev Biophys 46:505\u2013529. https:\/\/doi.org\/10.1146\/annurev-biophys-062215-010822","journal-title":"Annu Rev Biophys"},{"key":"1_CR99","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nbt.2842","volume":"32","author":"JD Sander","year":"2014","unstructured":"Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32:347\u2013355. https:\/\/doi.org\/10.1038\/nbt.2842","journal-title":"Nat Biotechnol"},{"key":"1_CR100","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/jpm8040038","volume":"8","author":"KRQ Lim","year":"2018","unstructured":"Lim KRQ, Yoon C, Yokota T (2018) Applications of CRISPR\/Cas9 for the treatment of Duchenne muscular dystrophy. J Pers Med 8:38. https:\/\/doi.org\/10.3390\/jpm8040038","journal-title":"J Pers Med"},{"key":"1_CR101","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.3390\/ijms20236041","volume":"20","author":"S Brezgin","year":"2019","unstructured":"Brezgin S, Kostyusheva A, Kostyushev D, Chulanov V (2019) Dead Cas systems: types, principles, and applications. Int J Mol Sci 20:6041. https:\/\/doi.org\/10.3390\/ijms20236041","journal-title":"Int J Mol Sci"},{"key":"1_CR102","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nbt.3803","volume":"35","author":"YB Kim","year":"2017","unstructured":"Kim YB, Komor AC, Levy JM et al (2017) Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. Nat Biotechnol 35:371\u2013376. https:\/\/doi.org\/10.1038\/nbt.3803","journal-title":"Nat Biotechnol"},{"key":"1_CR103","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli NM, Komor AC, Rees HA et al (2017) Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature 551:464\u2013471. https:\/\/doi.org\/10.1038\/nature24644","journal-title":"Nature"},{"key":"1_CR104","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.molcel.2018.09.002","volume":"72","author":"J Yuan","year":"2018","unstructured":"Yuan J, Ma Y, Huang T et al (2018) Genetic modulation of RNA splicing with a CRISPR-guided cytidine deaminase. Mol Cell 72:380\u2013394.e7. https:\/\/doi.org\/10.1016\/j.molcel.2018.09.002","journal-title":"Mol Cell"},{"key":"1_CR105","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nbt.4148","volume":"36","author":"S-M Ryu","year":"2018","unstructured":"Ryu S-M, Koo T, Kim K et al (2018) Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat Biotechnol 36:536\u2013539. https:\/\/doi.org\/10.1038\/nbt.4148","journal-title":"Nat Biotechnol"},{"key":"1_CR106","doi-asserted-by":"publisher","first-page":"eabg4910","DOI":"10.1126\/sciadv.abg4910","volume":"7","author":"F Chemello","year":"2021","unstructured":"Chemello F, Chai AC, Li H et al (2021) Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci Adv 7:eabg4910. https:\/\/doi.org\/10.1126\/sciadv.abg4910","journal-title":"Sci Adv"},{"key":"1_CR107","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/cr.2013.122","volume":"23","author":"AW Cheng","year":"2013","unstructured":"Cheng AW, Wang H, Yang H et al (2013) Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res 23:1163\u20131171. https:\/\/doi.org\/10.1038\/cr.2013.122","journal-title":"Cell Res"},{"key":"1_CR108","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","volume":"152","author":"LS Qi","year":"2013","unstructured":"Qi LS, Larson MH, Gilbert LA et al (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152:1173\u20131183. https:\/\/doi.org\/10.1016\/j.cell.2013.02.022","journal-title":"Cell"},{"key":"1_CR109","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","volume":"154","author":"LA Gilbert","year":"2013","unstructured":"Gilbert LA, Larson MH, Morsut L et al (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154:442\u2013451. https:\/\/doi.org\/10.1016\/j.cell.2013.06.044","journal-title":"Cell"},{"key":"1_CR110","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajhg.2015.11.012","volume":"98","author":"D Wojtal","year":"2016","unstructured":"Wojtal D, Kemaladewi DU, Malam Z et al (2016) Spell checking nature: versatility of CRISPR\/Cas9 for developing treatments for inherited disorders. Am J Hum Genet 98:90\u2013101. https:\/\/doi.org\/10.1016\/j.ajhg.2015.11.012","journal-title":"Am J Hum Genet"},{"key":"1_CR111","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.omtn.2020.08.031","volume":"22","author":"K Sengupta","year":"2020","unstructured":"Sengupta K, Mishra MK, Loro E et al (2020) Genome editing-mediated utrophin upregulation in Duchenne muscular dystrophy stem cells. Mol Ther \u2013 Nucleic Acids 22:500\u2013509. https:\/\/doi.org\/10.1016\/j.omtn.2020.08.031","journal-title":"Mol Ther \u2013 Nucleic Acids"},{"key":"1_CR112","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3390\/ijms21030733","volume":"21","author":"Q Nguyen","year":"2020","unstructured":"Nguyen Q, KRQ L, Yokota T et al (2020) Genome editing for the understanding and treatment of inherited cardiomyopathies. Int J Mol Sci 21:733. https:\/\/doi.org\/10.3390\/ijms21030733","journal-title":"Int J Mol Sci"},{"key":"1_CR113","doi-asserted-by":"publisher","unstructured":"Aslesh T, Erkut E, Yokota T (2021) Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing. Expert Opin Biol Ther 1\u201313. https:\/\/doi.org\/10.1080\/14712598.2021.1872539","DOI":"10.1080\/14712598.2021.1872539"},{"key":"1_CR114","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/genes11030342","volume":"11","author":"KRQ Lim","year":"2020","unstructured":"Lim KRQ, Nguyen Q, Dzierlega K et al (2020) CRISPR-generated animal models of Duchenne muscular dystrophy. Genes (Basel) 11:342. https:\/\/doi.org\/10.3390\/genes11030342","journal-title":"Genes (Basel)"},{"key":"1_CR115","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ng.2454","volume":"44","author":"RJLF Lemmers","year":"2012","unstructured":"Lemmers RJLF, Tawil R, Petek LM et al (2012) Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 44:1370\u20131374. https:\/\/doi.org\/10.1038\/ng.2454","journal-title":"Nat Genet"},{"key":"1_CR116","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1136\/jmedgenet-2019-106402","volume":"56","author":"R Goossens","year":"2019","unstructured":"Goossens R, van den Boogaard ML, Lemmers RJLF et al (2019) Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing. J Med Genet 56:828\u2013837. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106402","journal-title":"J Med Genet"},{"key":"1_CR117","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/mt.2015.200","volume":"24","author":"CL Himeda","year":"2016","unstructured":"Himeda CL, Jones TI, Jones PL (2016) CRISPR\/dCas9-mediated transcriptional inhibition ameliorates the epigenetic dysregulation at D4Z4 and represses DUX4-fl in FSH muscular dystrophy. Mol Ther 24:527\u2013535. https:\/\/doi.org\/10.1038\/mt.2015.200","journal-title":"Mol Ther"},{"key":"1_CR118","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.ymthe.2018.04.019","volume":"26","author":"CL Himeda","year":"2018","unstructured":"Himeda CL, Jones TI, Virbasius C-M et al (2018) Identification of epigenetic regulators of DUX4-fl for targeted therapy of facioscapulohumeral muscular dystrophy. Mol Ther 26:1797\u20131807. https:\/\/doi.org\/10.1016\/j.ymthe.2018.04.019","journal-title":"Mol Ther"},{"key":"1_CR119","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1016\/j.ymthe.2020.10.005","volume":"28","author":"S Marsh","year":"2020","unstructured":"Marsh S, Hanson B, Wood MJA et al (2020) Application of CRISPR-Cas9-mediated genome editing for the treatment of myotonic dystrophy type 1. Mol Ther 28:2527\u20132539. https:\/\/doi.org\/10.1016\/j.ymthe.2020.10.005","journal-title":"Mol Ther"},{"key":"1_CR120","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/mt.2016.40","volume":"24","author":"S Turan","year":"2016","unstructured":"Turan S, Farruggio AP, Srifa W et al (2016) Precise correction of disease mutations in induced pluripotent stem cells derived from patients with limb girdle muscular dystrophy. Mol Ther 24:685\u2013696. https:\/\/doi.org\/10.1038\/mt.2016.40","journal-title":"Mol Ther"},{"key":"1_CR121","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/nm.4367","volume":"23","author":"DU Kemaladewi","year":"2017","unstructured":"Kemaladewi DU, Maino E, Hyatt E et al (2017) Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. Nat Med 23:984\u2013989. https:\/\/doi.org\/10.1038\/nm.4367","journal-title":"Nat Med"},{"key":"1_CR122","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-019-1430-x","volume":"572","author":"DU Kemaladewi","year":"2019","unstructured":"Kemaladewi DU, Bassi PS, Erwood S et al (2019) A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene. Nature 572:125\u2013130. https:\/\/doi.org\/10.1038\/s41586-019-1430-x","journal-title":"Nature"},{"key":"1_CR123","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/brain\/awr342","volume":"135","author":"S Herson","year":"2012","unstructured":"Herson S, Hentati F, Rigolet A et al (2012) A phase I trial of adeno-associated virus serotype 1-\u03b3-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain 135:483\u2013492. https:\/\/doi.org\/10.1093\/brain\/awr342","journal-title":"Brain"},{"key":"1_CR124","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.omtm.2019.04.007","volume":"13","author":"D Israeli","year":"2019","unstructured":"Israeli D, Cosette J, Corre G et al (2019) An AAV-SGCG dose-response study in a \u03b3-sarcoglycanopathy mouse model in the context of mechanical stress. Mol Ther \u2013 Methods Clin Dev 13:494\u2013502. https:\/\/doi.org\/10.1016\/j.omtm.2019.04.007","journal-title":"Mol Ther \u2013 Methods Clin Dev"},{"key":"1_CR125","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ana.21732","volume":"66","author":"JR Mendell","year":"2009","unstructured":"Mendell JR, Rodino-Klapac LR, Rosales-Quintero X et al (2009) Limb-girdle muscular dystrophy type 2D gene therapy restores \u03b1-sarcoglycan and associated proteins. Ann Neurol 66:290\u2013297. https:\/\/doi.org\/10.1002\/ana.21732","journal-title":"Ann Neurol"},{"key":"1_CR126","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/ana.22251","volume":"68","author":"JR Mendell","year":"2010","unstructured":"Mendell JR, Rodino-Klapac LR, Rosales XQ et al (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68:629\u2013638. https:\/\/doi.org\/10.1002\/ana.22251","journal-title":"Ann Neurol"},{"key":"1_CR127","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1089\/hum.2019.006","volume":"30","author":"JR Mendell","year":"2019","unstructured":"Mendell JR, Chicoine LG, Al-Zaidy SA et al (2019) Gene delivery for limb-girdle muscular dystrophy type 2D by isolated limb infusion. Hum Gene Ther 30:794\u2013801. https:\/\/doi.org\/10.1089\/hum.2019.006","journal-title":"Hum Gene Ther"},{"key":"1_CR128","unstructured":"Sarepta Therapeutics (2021) Sarepta Therapeutics\u2019 investigational gene therapy SRP-9003 for the treatment of limb-girdle muscular dystrophy type 2E shows sustained expression and functional improvements 2 years after administration"},{"key":"1_CR129","unstructured":"Gurunathan S (2020) Sarepta therapeutics announces positive results from the SRP-9003 gene therapy trial to treat LGMD2E. https:\/\/strongly.mda.org\/sarepta-therapeutics-announces-positive-results-from-the-srp-9003-gene-therapy-trial-to-treat-lgmd2e\/. Accessed 7 June 2021"},{"key":"1_CR130","unstructured":"GeneTherapyLive (2021) SRP-9003 efficacy, tolerability sustained at 2 years in LGMD2E. https:\/\/www.genetherapylive.com\/view\/srp-9003-efficacy-tolerability-sustained-at-2-years-in-lgmd2e. Accessed 7 June 2021"},{"key":"1_CR131","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ymthe.2005.09.017","volume":"13","author":"M Bartoli","year":"2006","unstructured":"Bartoli M, Roudaut C, Martin S et al (2006) Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol Ther 13:250\u2013259. https:\/\/doi.org\/10.1016\/j.ymthe.2005.09.017","journal-title":"Mol Ther"},{"key":"1_CR132","doi-asserted-by":"publisher","first-page":"eaat6072","DOI":"10.1126\/scitranslmed.aat6072","volume":"11","author":"W Lostal","year":"2019","unstructured":"Lostal W, Roudaut C, Faivre M et al (2019) Titin splicing regulates cardiotoxicity associated with calpain 3 gene therapy for limb-girdle muscular dystrophy type 2A. Sci Transl Med 11:eaat6072. https:\/\/doi.org\/10.1126\/scitranslmed.aat6072","journal-title":"Sci Transl Med"},{"key":"1_CR133","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.omtm.2018.10.004","volume":"11","author":"CH Vannoy","year":"2018","unstructured":"Vannoy CH, Leroy V, Lu QL (2018) Dose-dependent effects of FKRP gene-replacement therapy on functional rescue and longevity in dystrophic mice. Mol Ther \u2013 Methods Clin Dev 11:106\u2013120. https:\/\/doi.org\/10.1016\/j.omtm.2018.10.004","journal-title":"Mol Ther \u2013 Methods Clin Dev"},{"key":"1_CR134","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/mt.2013.156","volume":"21","author":"L Xu","year":"2013","unstructured":"Xu L, Lu PJ, Wang C-H et al (2013) Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of \u03b1-dystroglycan and improves muscle functions. Mol Ther 21:1832\u20131840. https:\/\/doi.org\/10.1038\/mt.2013.156","journal-title":"Mol Ther"},{"key":"1_CR135","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1038\/mt.2014.141","volume":"22","author":"C Qiao","year":"2014","unstructured":"Qiao C, Wang C-H, Zhao C et al (2014) Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery. Mol Ther 22:1890\u20131899. https:\/\/doi.org\/10.1038\/mt.2014.141","journal-title":"Mol Ther"},{"key":"1_CR136","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1093\/hmg\/ddx066","volume":"26","author":"E Gicquel","year":"2017","unstructured":"Gicquel E, Maizonnier N, Foltz SJ et al (2017) AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression. Hum Mol Genet 26:1952\u20131965. https:\/\/doi.org\/10.1093\/hmg\/ddx066","journal-title":"Hum Mol Genet"},{"key":"1_CR137","doi-asserted-by":"publisher","first-page":"220ra10","DOI":"10.1126\/scitranslmed.3007523","volume":"6","author":"MK Childers","year":"2014","unstructured":"Childers MK, Joubert R, Poulard K et al (2014) Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med 6:220ra10. https:\/\/doi.org\/10.1126\/scitranslmed.3007523","journal-title":"Sci Transl Med"},{"key":"1_CR138","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ymthe.2017.02.004","volume":"25","author":"DL Mack","year":"2017","unstructured":"Mack DL, Poulard K, Goddard MA et al (2017) Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs. Mol Ther 25:839\u2013854. https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.004","journal-title":"Mol Ther"},{"key":"1_CR139","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1089\/hum.2020.217","volume":"31","author":"PB Shieh","year":"2020","unstructured":"Shieh PB, B\u00f6nnemann CG, M\u00fcller-Felber W et al (2020) Re: \u201cmoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d by Wilson and Flotte. Hum Gene Ther 31:787\u2013787. https:\/\/doi.org\/10.1089\/hum.2020.217","journal-title":"Hum Gene Ther"},{"key":"1_CR140","unstructured":"Audentes Therapeutics (2020) Letter to XLMTM patient community. https:\/\/myotubulartrust.org\/wp-content\/uploads\/23JUNE2020-Letter-to-Patient-Community_Sent.pdf. Accessed 7 June 2021"},{"key":"1_CR141","unstructured":"Audentes Therapeutics (2020) Audentes therapeutics provides update on the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy. https:\/\/www.audentestx.com\/press_release\/audentes-therapeutics-provides-update-on-the-aspiro-clinical-trial-evaluating-at132-in-patients-with-x-linked-myotubular-myopathy\/. Accessed 7 June 2021"},{"key":"1_CR142","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","volume":"38","author":"Nature Biotechnology","year":"2020","unstructured":"Nature Biotechnology (2020) High-dose AAV gene therapy deaths. Nat Biotechnol 38:910\u2013910. https:\/\/doi.org\/10.1038\/s41587-020-0642-9","journal-title":"Nat Biotechnol"},{"key":"1_CR143","unstructured":"Audentes Therapeutics (2020) Hold lifted by FDA on ASPIRO clinical trial of AT132 for treatment of X-linked myotubular myopathy (XLMTM). https:\/\/www.astellas.com\/en\/news\/16301. Accessed 7 June 2021"},{"key":"1_CR144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039233","volume":"7","author":"WE Grose","year":"2012","unstructured":"Grose WE, Clark KR, Griffin D et al (2012) Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One 7:e39233. https:\/\/doi.org\/10.1371\/journal.pone.0039233","journal-title":"PLoS One"},{"key":"1_CR145","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1089\/hum.2017.062","volume":"29","author":"RA Potter","year":"2018","unstructured":"Potter RA, Griffin DA, Sondergaard PC et al (2018) Systemic delivery of dysferlin overlap vectors provides long-term gene expression and functional improvement for dysferlinopathy. Hum Gene Ther 29:749\u2013762. https:\/\/doi.org\/10.1089\/hum.2017.062","journal-title":"Hum Gene Ther"},{"key":"1_CR146","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/acn3.172","volume":"2","author":"PC Sondergaard","year":"2015","unstructured":"Sondergaard PC, Griffin DA, Pozsgai ER et al (2015) AAV dysferlin overlap vectors restore function in dysferlinopathy animal models. Ann Clin Transl Neurol 2:256\u2013270. https:\/\/doi.org\/10.1002\/acn3.172","journal-title":"Ann Clin Transl Neurol"},{"key":"1_CR147","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan D (2018) Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther 26:2337\u20132356. https:\/\/doi.org\/10.1016\/j.ymthe.2018.07.011","journal-title":"Mol Ther"},{"key":"1_CR148","unstructured":"Gonzalez P (2020) SGT-001 microdystrophin gene therapy for Duchenne muscular dystrophy. https:\/\/s3.us-east-2.amazonaws.com\/solid-bio-assets.investeddigital.com\/pubs\/Gonzalez_ASGCT_2020_11May2020.pdf. Accessed 29 Apr 2021"},{"key":"1_CR149","unstructured":"Pfizer (2021) Pfizer doses first participant in phase 3 study for Duchenne muscular dystrophy investigational gene therapy. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-doses-first-participant-phase-3-study-duchenne. Accessed 25 Apr 2021"},{"key":"1_CR150","unstructured":"Pfizer (2020) Pfizer\u2019s new phase 1B results of gene therapy in ambulatory boys with Duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys. Accessed 25 Apr 2021"},{"key":"1_CR151","unstructured":"Sarepta (2021) Sarepta therapeutics announces top-line results for part 1 of study 102 evaluating SRP-9001, its investigational gene therapy for the treatment of Duchenne muscular dystrophy. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-top-line-results-part-1-study-102. Accessed 25 Apr 2021"},{"key":"1_CR152","unstructured":"Genetic Engineering & Biotechnology News (2019) FDA places another clinical hold on trial for solid\u2019s DMD gene therapy. https:\/\/www.genengnews.com\/news\/fda-places-another-clinical-hold-on-trial-for-solids-dmd-gene-therapy\/. Accessed 7 June 2021"},{"key":"1_CR153","unstructured":"Solid Biosciences (2020) Solid biosciences announces FDA lifts clinical hold on IGNITE DMD clinical trial. https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-announces-fda-lifts-clinical-hold-on-ignite-dmd-clinical-trial. Accessed 7 June 2021"},{"key":"1_CR154","unstructured":"Genethon (2021) Genethon announces first patient dosed in clinical trial of investigational gene therapy GNT 0004 for Duchenne muscular dystrophy. https:\/\/www.genethon.fr\/wp-content\/uploads\/2021\/04\/PR_GENETHON_DMD-1.pdf. Accessed 25 Apr 2021"},{"key":"1_CR155","doi-asserted-by":"publisher","first-page":"50ra69","DOI":"10.1126\/scitranslmed.3000951","volume":"2","author":"M Krahn","year":"2010","unstructured":"Krahn M, Wein N, Bartoli M et al (2010) A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci Transl Med 2:50ra69. https:\/\/doi.org\/10.1126\/scitranslmed.3000951","journal-title":"Sci Transl Med"},{"key":"1_CR156","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.omtm.2021.02.004","volume":"21","author":"D Packer","year":"2021","unstructured":"Packer D, Martin PT (2021) Micro-laminin gene therapy can function as an inhibitor of muscle disease in the dyW mouse model of MDC1A. Mol Ther \u2013 Methods Clin Dev 21:274\u2013287. https:\/\/doi.org\/10.1016\/j.omtm.2021.02.004","journal-title":"Mol Ther \u2013 Methods Clin Dev"},{"key":"1_CR157","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.ymthe.2019.10.011","volume":"27","author":"D Duan","year":"2019","unstructured":"Duan D (2019) Micro-utrophin therapy for Duchenne muscular dystrophy. Mol Ther 27:1872\u20131874. https:\/\/doi.org\/10.1016\/j.ymthe.2019.10.011","journal-title":"Mol Ther"},{"key":"1_CR158","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1089\/hum.2013.092","volume":"24","author":"KM Flanigan","year":"2013","unstructured":"Flanigan KM, Campbell K, Viollet L et al (2013) Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther 24:797\u2013806. https:\/\/doi.org\/10.1089\/hum.2013.092","journal-title":"Hum Gene Ther"},{"key":"1_CR159","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell JR, Campbell K, Rodino-Klapac L et al (2010) Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N Engl J Med 363:1429\u20131437. https:\/\/doi.org\/10.1056\/NEJMoa1000228","journal-title":"N Engl J Med"},{"key":"1_CR160","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","volume":"25","author":"Y Song","year":"2019","unstructured":"Song Y, Morales L, Malik AS et al (2019) Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nat Med 25:1505\u20131511. https:\/\/doi.org\/10.1038\/s41591-019-0594-0","journal-title":"Nat Med"},{"key":"1_CR161","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2018.10.005","volume":"11","author":"TL Kennedy","year":"2018","unstructured":"Kennedy TL, Guiraud S, Edwards B et al (2018) Micro-utrophin improves cardiac and skeletal muscle function of severely affected D2\/mdx mice. Mol Ther \u2013 Methods Clin Dev 11:92\u2013105. https:\/\/doi.org\/10.1016\/j.omtm.2018.10.005","journal-title":"Mol Ther \u2013 Methods Clin Dev"},{"key":"1_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1009179","volume":"16","author":"GB Banks","year":"2020","unstructured":"Banks GB, Chamberlain JS, Odom GL (2020) Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects. PLoS Genet 16:e1009179. https:\/\/doi.org\/10.1371\/journal.pgen.1009179","journal-title":"PLoS Genet"},{"key":"1_CR163","doi-asserted-by":"publisher","first-page":"11748","DOI":"10.1073\/pnas.0604970103","volume":"103","author":"RN Kanadia","year":"2006","unstructured":"Kanadia RN, Shin J, Yuan Y et al (2006) Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci 103:11748\u201311753. https:\/\/doi.org\/10.1073\/pnas.0604970103","journal-title":"Proc Natl Acad Sci"},{"key":"1_CR164","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/35095054","volume":"413","author":"J Moll","year":"2001","unstructured":"Moll J, Barzaghi P, Lin S et al (2001) An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 413:302\u2013307. https:\/\/doi.org\/10.1038\/35095054","journal-title":"Nature"},{"key":"1_CR165","doi-asserted-by":"publisher","first-page":"11999","DOI":"10.1073\/pnas.0502137102","volume":"102","author":"C Qiao","year":"2005","unstructured":"Qiao C, Li J, Zhu T et al (2005) Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc Natl Acad Sci U S A 102:11999\u201312004. https:\/\/doi.org\/10.1073\/pnas.0502137102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR166","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omtm.2018.01.005","volume":"9","author":"C Qiao","year":"2018","unstructured":"Qiao C, Dai Y, Nikolova VD et al (2018) Amelioration of muscle and nerve pathology in LAMA2 muscular dystrophy by AAV9-mini-agrin. Mol Ther \u2013 Methods Clin Dev 9:47\u201356. https:\/\/doi.org\/10.1016\/j.omtm.2018.01.005","journal-title":"Mol Ther \u2013 Methods Clin Dev"},{"key":"1_CR167","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ymthe.2019.12.011","volume":"28","author":"NB Wasala","year":"2020","unstructured":"Wasala NB, Yue Y, Lostal W et al (2020) Single SERCA2a therapy ameliorated dilated cardiomyopathy for 18 months in a mouse model of Duchenne muscular dystrophy. Mol Ther 28:845\u2013854. https:\/\/doi.org\/10.1016\/j.ymthe.2019.12.011","journal-title":"Mol Ther"},{"key":"1_CR168","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1172\/JCI43844","volume":"121","author":"SA Goonasekera","year":"2011","unstructured":"Goonasekera SA, Lam CK, Millay DP et al (2011) Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J Clin Invest 121:1044\u20131052. https:\/\/doi.org\/10.1172\/JCI43844","journal-title":"J Clin Invest"},{"key":"1_CR169","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1073\/pnas.0709144105","volume":"105","author":"AM Haidet","year":"2008","unstructured":"Haidet AM, Rizo L, Handy C et al (2008) Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci 105:4318\u20134322. https:\/\/doi.org\/10.1073\/pnas.0709144105","journal-title":"Proc Natl Acad Sci"},{"key":"1_CR170","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123538","volume":"3","author":"CR Giesige","year":"2018","unstructured":"Giesige CR, Wallace LM, Heller KN et al (2018) AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight 3:e123538. https:\/\/doi.org\/10.1172\/jci.insight.123538","journal-title":"JCI Insight"},{"key":"1_CR171","doi-asserted-by":"publisher","first-page":"6ra15","DOI":"10.1126\/scitranslmed.3000112","volume":"1","author":"J Kota","year":"2009","unstructured":"Kota J, Handy CR, Haidet AM et al (2009) Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 1:6ra15. https:\/\/doi.org\/10.1126\/scitranslmed.3000112","journal-title":"Sci Transl Med"},{"key":"1_CR172","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.nmd.2006.12.004","volume":"17","author":"R Xu","year":"2007","unstructured":"Xu R, Camboni M, Martin PT (2007) Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: evidence for a utrophin-independent mechanism. Neuromuscul Disord 17:209\u2013220. https:\/\/doi.org\/10.1016\/j.nmd.2006.12.004","journal-title":"Neuromuscul Disord"},{"key":"1_CR173","doi-asserted-by":"publisher","first-page":"C476","DOI":"10.1152\/ajpcell.00456.2008","volume":"296","author":"PT Martin","year":"2009","unstructured":"Martin PT, Xu R, Rodino-Klapac LR et al (2009) Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. Am J Physiol Physiol 296:C476\u2013C488. https:\/\/doi.org\/10.1152\/ajpcell.00456.2008","journal-title":"Am J Physiol Physiol"},{"key":"1_CR174","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2019.01.005","volume":"27","author":"R Xu","year":"2019","unstructured":"Xu R, Jia Y, Zygmunt DA, Martin PT (2019) rAAVrh74.MCK.GALGT2 protects against loss of hemodynamic function in the aging mdx mouse heart. Mol Ther 27:636\u2013649. https:\/\/doi.org\/10.1016\/j.ymthe.2019.01.005","journal-title":"Mol Ther"},{"key":"1_CR175","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2353\/ajpath.2007.060927","volume":"171","author":"R Xu","year":"2007","unstructured":"Xu R, Chandrasekharan K, Yoon JH et al (2007) Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. Am J Pathol 171:181\u2013199. https:\/\/doi.org\/10.2353\/ajpath.2007.060927","journal-title":"Am J Pathol"},{"key":"1_CR176","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2353\/ajpath.2009.080967","volume":"175","author":"R Xu","year":"2009","unstructured":"Xu R, DeVries S, Camboni M, Martin PT (2009) Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice. Am J Pathol 175:235\u2013247. https:\/\/doi.org\/10.2353\/ajpath.2009.080967","journal-title":"Am J Pathol"},{"key":"1_CR177","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1016\/j.ajpath.2016.05.021","volume":"186","author":"PJ Thomas","year":"2016","unstructured":"Thomas PJ, Xu R, Martin PT (2016) B4GALNT2 (GALGT2) gene therapy reduces skeletal muscle pathology in the FKRP P448L mouse model of limb girdle muscular dystrophy 2I. Am J Pathol 186:2429\u20132448. https:\/\/doi.org\/10.1016\/j.ajpath.2016.05.021","journal-title":"Am J Pathol"},{"key":"1_CR178","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/mt.2013.246","volume":"22","author":"LG Chicoine","year":"2014","unstructured":"Chicoine LG, Rodino-Klapac LR, Shao G et al (2014) Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin \u03b12 surrogates. Mol Ther 22:713\u2013724. https:\/\/doi.org\/10.1038\/mt.2013.246","journal-title":"Mol Ther"},{"key":"1_CR179","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/mt.2014.200","volume":"23","author":"JR Mendell","year":"2015","unstructured":"Mendell JR, Sahenk Z, Malik V et al (2015) A phase 1\/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther 23:192\u2013201. https:\/\/doi.org\/10.1038\/mt.2014.200","journal-title":"Mol Ther"},{"key":"1_CR180","unstructured":"Mendell JR (2020) Study results: clinical intramuscular gene transfer of rAAV1.CMV.huFollistatin344 trial to patients with Duchenne muscular dystrophy. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02354781. Accessed 7 June 2021"},{"key":"1_CR181","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1172\/JCI142031","volume":"130","author":"S Biressi","year":"2020","unstructured":"Biressi S, Filareto A, Rando TA (2020) Stem cell therapy for muscular dystrophies. J Clin Invest 130:5652\u20135664. https:\/\/doi.org\/10.1172\/JCI142031","journal-title":"J Clin Invest"},{"key":"1_CR182","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s12015-020-10100-y","volume":"17","author":"CRM Ausems","year":"2021","unstructured":"Ausems CRM, van Engelen BGM, van Bokhoven H, Wansink DG (2021) Systemic cell therapy for muscular dystrophies. Stem Cell Rev Rep 17:878\u2013899. https:\/\/doi.org\/10.1007\/s12015-020-10100-y","journal-title":"Stem Cell Rev Rep"},{"key":"1_CR183","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/mt.2013.155","volume":"22","author":"S P\u00e9ri\u00e9","year":"2014","unstructured":"P\u00e9ri\u00e9 S, Trollet C, Mouly V et al (2014) Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I\/Iia clinical study. Mol Ther 22:219\u2013225. https:\/\/doi.org\/10.1038\/mt.2013.155","journal-title":"Mol Ther"},{"key":"1_CR184","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bbadis.2006.10.003","volume":"1772","author":"A Abu-Baker","year":"2007","unstructured":"Abu-Baker A, Rouleau GA (2007) Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies. Biochim Biophys Acta Mol basis Dis 1772:173\u2013185. https:\/\/doi.org\/10.1016\/j.bbadis.2006.10.003","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"1_CR185","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ng0298-164","volume":"18","author":"B Brais","year":"1998","unstructured":"Brais B, Bouchard J-P, Xie Y-G et al (1998) Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 18:164\u2013167. https:\/\/doi.org\/10.1038\/ng0298-164","journal-title":"Nat Genet"},{"key":"1_CR186","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.csbj.2020.03.012","volume":"18","author":"Y Jin","year":"2020","unstructured":"Jin Y, Shen Y, Su X et al (2020) Effective restoration of dystrophin expression in iPSC Mdx-derived muscle progenitor cells using the CRISPR\/Cas9 system and homology-directed repair technology. Comput Struct Biotechnol J 18:765\u2013773. https:\/\/doi.org\/10.1016\/j.csbj.2020.03.012","journal-title":"Comput Struct Biotechnol J"},{"key":"1_CR187","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","volume":"18","author":"CS Young","year":"2016","unstructured":"Young CS, Hicks MR, Ermolova NV et al (2016) A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell 18:533\u2013540. https:\/\/doi.org\/10.1016\/j.stem.2016.01.021","journal-title":"Cell Stem Cell"},{"key":"1_CR188","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.ymthe.2019.08.011","volume":"27","author":"S Selvaraj","year":"2019","unstructured":"Selvaraj S, Dhoke NR, Kiley J et al (2019) Gene correction of LGMD2A patient-specific iPSCs for the development of targeted autologous cell therapy. Mol Ther 27:2147\u20132157. https:\/\/doi.org\/10.1016\/j.ymthe.2019.08.011","journal-title":"Mol Ther"},{"key":"1_CR189","doi-asserted-by":"publisher","first-page":"140ra89","DOI":"10.1126\/scitranslmed.3003541","volume":"4","author":"FS Tedesco","year":"2012","unstructured":"Tedesco FS, Gerli MFM, Perani L et al (2012) Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci Transl Med 4:140ra89\u2013140ra89. https:\/\/doi.org\/10.1126\/scitranslmed.3003541","journal-title":"Sci Transl Med"},{"key":"1_CR190","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1177\/0883073810371129","volume":"25","author":"RS Finkel","year":"2010","unstructured":"Finkel RS (2010) Read-through strategies for suppression of nonsense mutations in Duchenne\/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 25:1158\u20131164. https:\/\/doi.org\/10.1177\/0883073810371129","journal-title":"J Child Neurol"},{"key":"1_CR191","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1073\/pnas.1424127112","volume":"112","author":"B Roy","year":"2015","unstructured":"Roy B, Leszyk JD, Mangus DA, Jacobson A (2015) Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3. Proc Natl Acad Sci 112:3038\u20133043. https:\/\/doi.org\/10.1073\/pnas.1424127112","journal-title":"Proc Natl Acad Sci"},{"key":"1_CR192","doi-asserted-by":"publisher","first-page":"12508","DOI":"10.1073\/pnas.1605336113","volume":"113","author":"B Roy","year":"2016","unstructured":"Roy B, Friesen WJ, Tomizawa Y et al (2016) Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc Natl Acad Sci 113:12508\u201312513. https:\/\/doi.org\/10.1073\/pnas.1605336113","journal-title":"Proc Natl Acad Sci"},{"key":"1_CR193","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1073\/pnas.51.5.883","volume":"51","author":"J Davies","year":"1964","unstructured":"Davies J, Gilbert W, Gorini L (1964) Streptomycin, suppression, and the code. Proc Natl Acad Sci 51:883\u2013890. https:\/\/doi.org\/10.1073\/pnas.51.5.883","journal-title":"Proc Natl Acad Sci"},{"key":"1_CR194","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/1756285610388693","volume":"3","author":"V Malik","year":"2010","unstructured":"Malik V, Rodino-Klapac LR, Viollet L, Mendell JR (2010) Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Ther Adv Neurol Disord 3:379\u2013389. https:\/\/doi.org\/10.1177\/1756285610388693","journal-title":"Ther Adv Neurol Disord"},{"key":"1_CR195","doi-asserted-by":"publisher","unstructured":"Bertoni C, Namgoong J (2016) Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy. Degener Neurol Neuromuscul Dis 37. https:\/\/doi.org\/10.2147\/DNND.S71808","DOI":"10.2147\/DNND.S71808"},{"key":"1_CR196","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature05756","volume":"447","author":"EM Welch","year":"2007","unstructured":"Welch EM, Barton ER, Zhuo J et al (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87\u201391. https:\/\/doi.org\/10.1038\/nature05756","journal-title":"Nature"},{"key":"1_CR197","unstructured":"European Medicines Agency (2014) European Medicines Agency recommends first-in-class medicine for treatment of Duchenne muscular dystrophy. https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-recommends-first-class-medicine-treatment-duchenne-muscular-dystrophy. Accessed 9 June 2021"},{"key":"1_CR198","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081302","volume":"8","author":"RS Finkel","year":"2013","unstructured":"Finkel RS, Flanigan KM, Wong B et al (2013) Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One 8:e81302. https:\/\/doi.org\/10.1371\/journal.pone.0081302","journal-title":"PLoS One"},{"key":"1_CR199","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby K, Finkel R, Wong B et al (2014) Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50:477\u2013487. https:\/\/doi.org\/10.1002\/mus.24332","journal-title":"Muscle Nerve"},{"key":"1_CR200","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE et al (2017) Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1489\u20131498. https:\/\/doi.org\/10.1016\/S0140-6736(17)31611-2","journal-title":"Lancet"},{"key":"1_CR201","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2217\/cer-2020-0095","volume":"9","author":"C Campbell","year":"2020","unstructured":"Campbell C, Barohn RJ, Bertini E et al (2020) Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res 9:973\u2013984. https:\/\/doi.org\/10.2217\/cer-2020-0095","journal-title":"J Comp Eff Res"},{"key":"1_CR202","unstructured":"Gardner J (2021) PTC aims again for FDA review of Duchenne drug despite latest miss. https:\/\/www.biopharmadive.com\/news\/ptc-duchenne-data-fourth-fda-review\/594642\/. Accessed 9 June 2021"},{"key":"1_CR203","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/cer-2019-0086","volume":"8","author":"F Muntoni","year":"2019","unstructured":"Muntoni F, Desguerre I, Guglieri M et al (2019) Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry. J Comp Eff Res 8:1187\u20131200. https:\/\/doi.org\/10.2217\/cer-2019-0086","journal-title":"J Comp Eff Res"},{"key":"1_CR204","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2217\/cer-2019-0171","volume":"9","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Muntoni F, Osorio AN et al (2020) Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res 9:341\u2013360. https:\/\/doi.org\/10.2217\/cer-2019-0171","journal-title":"J Comp Eff Res"},{"key":"1_CR205","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.omtm.2021.04.015","volume":"21","author":"K Seo","year":"2021","unstructured":"Seo K, Kim EK, Choi J et al (2021) Functional recovery of a novel knockin mouse model of dysferlinopathy by readthrough of nonsense mutation. Mol Ther \u2013 Methods Clin Dev 21:702\u2013709. https:\/\/doi.org\/10.1016\/j.omtm.2021.04.015","journal-title":"Mol Ther \u2013 Methods Clin Dev"},{"key":"1_CR206","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","volume":"15","author":"KM Keeling","year":"2014","unstructured":"Keeling KM, Xue X, Gunn G, Bedwell DM (2014) Therapeutics based on stop codon readthrough. Annu Rev Genomics Hum Genet 15:371\u2013394. https:\/\/doi.org\/10.1146\/annurev-genom-091212-153527","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"1_CR207","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/2472630317692561","volume":"22","author":"F Liang","year":"2017","unstructured":"Liang F, Shang H, Jordan NJ et al (2017) High-throughput screening for readthrough modulators of CFTR PTC mutations. SLAS Technol Transl Life Sci Innov 22:315\u2013324. https:\/\/doi.org\/10.1177\/2472630317692561","journal-title":"SLAS Technol Transl Life Sci Innov"},{"key":"1_CR208","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/jcm9020289","volume":"9","author":"M Borgatti","year":"2020","unstructured":"Borgatti M, Altamura E, Salvatori F et al (2020) Screening readthrough compounds to suppress nonsense mutations: possible application to \u03b2-thalassemia. J Clin Med 9:289. https:\/\/doi.org\/10.3390\/jcm9020289","journal-title":"J Clin Med"},{"key":"1_CR209","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1177\/1060028019900500","volume":"54","author":"M Bylo","year":"2020","unstructured":"Bylo M, Farewell R, Coppenrath VA, Yogaratnam D (2020) A review of deflazacort for patients with Duchenne muscular dystrophy. Ann Pharmacother 54:788\u2013794. https:\/\/doi.org\/10.1177\/1060028019900500","journal-title":"Ann Pharmacother"},{"key":"1_CR210","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-021-01758-9","volume":"16","author":"S Kourakis","year":"2021","unstructured":"Kourakis S, Timpani CA, Campelj DG et al (2021) Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: can we do better? Orphanet J Rare Dis 16:117. https:\/\/doi.org\/10.1186\/s13023-021-01758-9","journal-title":"Orphanet J Rare Dis"},{"key":"1_CR211","doi-asserted-by":"publisher","unstructured":"Timmermans S, Souffriau J, Libert C (2019) A general introduction to glucocorticoid biology. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.01545","DOI":"10.3389\/fimmu.2019.01545"},{"key":"1_CR212","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/mus.26736","volume":"61","author":"CM McDonald","year":"2020","unstructured":"McDonald CM, Sajeev G, Yao Z et al (2020) Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve 61:26\u201335. https:\/\/doi.org\/10.1002\/mus.26736","journal-title":"Muscle Nerve"},{"key":"1_CR213","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs RC, Miller JP, Greenberg CR et al (2016) Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology 87:2123\u20132131. https:\/\/doi.org\/10.1212\/WNL.0000000000003217","journal-title":"Neurology"},{"key":"1_CR214","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2217\/cer-2019-0170","volume":"9","author":"JR Marden","year":"2020","unstructured":"Marden JR, Freimark J, Yao Z et al (2020) Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center. J Comp Eff Res 9:177\u2013189. https:\/\/doi.org\/10.2217\/cer-2019-0170","journal-title":"J Comp Eff Res"},{"key":"1_CR215","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/mus.26191","volume":"58","author":"PB Shieh","year":"2018","unstructured":"Shieh PB, Mcintosh J, Jin F et al (2018) Deflazacort versus prednisone\/prednisolone for maintaining motor function and delaying loss of ambulation: a post HOC analysis from the ACT DMD trial. Muscle Nerve 58:639\u2013645. https:\/\/doi.org\/10.1002\/mus.26191","journal-title":"Muscle Nerve"},{"key":"1_CR216","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP et al (2015) Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology 85:1048\u20131055. https:\/\/doi.org\/10.1212\/WNL.0000000000001950","journal-title":"Neurology"},{"key":"1_CR217","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","volume":"21","author":"EKM Reeves","year":"2013","unstructured":"Reeves EKM, Hoffman EP, Nagaraju K et al (2013) VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem 21:2241\u20132249. https:\/\/doi.org\/10.1016\/j.bmc.2013.02.009","journal-title":"Bioorg Med Chem"},{"key":"1_CR218","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/emmm.201302621","volume":"5","author":"CR Heier","year":"2013","unstructured":"Heier CR, Damsker JM, Yu Q et al (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 5:1569\u20131585. https:\/\/doi.org\/10.1002\/emmm.201302621","journal-title":"EMBO Mol Med"},{"key":"1_CR219","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1124\/jpet.112.194340","volume":"343","author":"AR Baudy","year":"2012","unstructured":"Baudy AR, Reeves EKM, Damsker JM et al (2012) \u0394-9,11 modification of glucocorticoids dissociates nuclear factor-\u03baB inhibitory efficacy from glucocorticoid response element-associated side effects. J Pharmacol Exp Ther 343:225\u2013232. https:\/\/doi.org\/10.1124\/jpet.112.194340","journal-title":"J Pharmacol Exp Ther"},{"key":"1_CR220","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003222","volume":"17","author":"EC Smith","year":"2020","unstructured":"Smith EC, Conklin LS, Hoffman EP et al (2020) Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study. PLoS Med 17:e1003222. https:\/\/doi.org\/10.1371\/journal.pmed.1003222","journal-title":"PLoS Med"},{"key":"1_CR221","unstructured":"Santhera Pharmaceuticals (2021) Santhera and ReveraGen announce new 2.5-year treatment data with vamorolone in Duchenne muscular dystrophy. https:\/\/www.globenewswire.com\/news-release\/2021\/04\/28\/2218239\/0\/en\/Santhera-and-ReveraGen-Announce-New-2-5-year-Treatment-Data-with-Vamorolone-in-Duchenne-Muscular-Dystrophy.html. Accessed 9 June 2021"},{"key":"1_CR222","unstructured":"Santhera Pharmaceuticals and ReveraGen BioPharma (2021) Santhera and ReveraGen announce positive and statistically highly significant topline results with vamorolone in pivotal VISION-DMD study. https:\/\/www.santhera.com\/assets\/files\/press-releases\/2021-06-01_PR_VamTopline_e_final.pdf. Accessed 9 June 2021"},{"key":"1_CR223","doi-asserted-by":"publisher","unstructured":"Cordova G, Negroni E, Cabello-Verrugio C et al (2018) Combined therapies for Duchenne muscular dystrophy to optimize treatment efficacy. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2018.00114","DOI":"10.3389\/fgene.2018.00114"},{"key":"1_CR224","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1093\/hmg\/ddt342","volume":"22","author":"LR Rodino-Klapac","year":"2013","unstructured":"Rodino-Klapac LR, Janssen PML, Shontz KM et al (2013) Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Hum Mol Genet 22:4929\u20134937. https:\/\/doi.org\/10.1093\/hmg\/ddt342","journal-title":"Hum Mol Genet"},{"key":"1_CR225","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ymthe.2005.04.001","volume":"12","author":"S Abmayr","year":"2005","unstructured":"Abmayr S, Gregorevic P, Allen JM, Chamberlain JS (2005) Phenotypic improvement of dystrophic muscles by rAAV\/microdystrophin vectors is augmented by Igf1 codelivery. Mol Ther 12:441\u2013450. https:\/\/doi.org\/10.1016\/j.ymthe.2005.04.001","journal-title":"Mol Ther"},{"key":"1_CR226","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.omtn.2018.02.002","volume":"11","author":"DW Wang","year":"2018","unstructured":"Wang DW, Mokhonova EI, Kendall GC et al (2018) Repurposing dantrolene for long-term combination therapy to potentiate antisense-mediated DMD exon skipping in the mdx mouse. Mol Ther \u2013 Nucleic Acids 11:180\u2013191. https:\/\/doi.org\/10.1016\/j.omtn.2018.02.002","journal-title":"Mol Ther \u2013 Nucleic Acids"},{"key":"1_CR227","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.omtn.2019.09.020","volume":"18","author":"F Barth\u00e9l\u00e9my","year":"2019","unstructured":"Barth\u00e9l\u00e9my F, Wang RT, Hsu C et al (2019) Targeting RyR activity boosts antisense exon 44 and 45 skipping in human DMD skeletal or cardiac muscle culture models. Mol Ther \u2013 Nucleic Acids 18:580\u2013589. https:\/\/doi.org\/10.1016\/j.omtn.2019.09.020","journal-title":"Mol Ther \u2013 Nucleic Acids"},{"key":"1_CR228","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008348","volume":"4","author":"DA O\u2019Leary","year":"2009","unstructured":"O\u2019Leary DA, Sharif O, Anderson P et al (2009) Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening. PLoS One 4:e8348. https:\/\/doi.org\/10.1371\/journal.pone.0008348","journal-title":"PLoS One"},{"key":"1_CR229","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/cdd.2009.160","volume":"17","author":"M Quattrocelli","year":"2010","unstructured":"Quattrocelli M, Cassano M, Crippa S et al (2010) Cell therapy strategies and improvements for muscular dystrophy. Cell Death Differ 17:1222\u20131229. https:\/\/doi.org\/10.1038\/cdd.2009.160","journal-title":"Cell Death Differ"}],"container-title":["Methods in Molecular Biology","Muscular Dystrophy Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2772-3_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T07:07:04Z","timestamp":1677654424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2772-3_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"ISBN":["9781071627716","9781071627723"],"references-count":229,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2772-3_1","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"19 November 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}